Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 6;8(4):172-179.
doi: 10.4103/bc.bc_52_22. eCollection 2022 Oct-Dec.

Neuroprotective approach in acute ischemic stroke: A systematic review of clinical and experimental studies

Fettah Eren  1 , Sueda Ecem Yilmaz  2
Affiliations
Review

Neuroprotective approach in acute ischemic stroke: A systematic review of clinical and experimental studies

Fettah Eren et al. Brain Circ. .

Abstract

Ischemic stroke is a disease with worldwide economic and social negative effects. It is a serious disease with high disability and mortality. Ionic imbalance, excitotoxicity, oxidative stress, and inflammation are induced during and after ischemic stroke. Cellular dysfunction, apoptosis, and necrosis are activated directly or indirectly mechanisms. The studies about neuroprotection in neurodegenerative diseases have increased in recent years. Data about the mechanisms of progressive molecular improvement in the brain tissue are increasing in acute ischemic stroke. Based on these data, preclinical and clinical studies on new neuroprotective treatments are being designed. An effective neuroprotective strategy can prolong the indication period of recanalization treatments in the acute stage of ischemic stroke. In addition, it can reduce neuronal necrosis and protect the brain against ischemia-related reperfusion injury. The current review has evaluated the recent clinical and experimental studies. The molecular mechanism of each of the neuroprotective strategies is also summarized. This review may help develop future strategies for combination treatment to protect the cerebral tissue from ischemia-reperfusion injury.

Keywords: Clinical trials; ischemic stroke; neuroprotection; neuroprotective agents; preclinical studies.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Goenka L, Uppugunduri Satyanarayana CR, Suresh Kumar S, George M. Neuroprotective agents in acute ischemic stroke-a reality check. Biomed Pharmacother. 2019;109:2539–47. - PubMed
    1. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001;32:1832–40. - PubMed
    1. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the merci retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet. 2012;380:1241–9. - PubMed
    1. Chamorro Á, Lo EH, Renú A, van Leyen K, Lyden PD. The future of neuroprotection in stroke. J Neurol Neurosurg Psychiatry. 2021;92:129–35. - PubMed
    1. Green AR. Pharmacological approaches to acute ischaemic stroke: Reperfusion certainly, neuroprotection possibly. Br J Pharmacol. 2008;153(Suppl 1):S325–38. - PMC - PubMed